Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
NCT00004012Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 1998
- Primary completion
- Dec 2000
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 1998; status: completed.
02
Drugs
capecitabine
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00004012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004012.